Brasil Pharma : Material Fact 02/02/2018

Free translation

BRASIL PHARMA S.A. - IN JUDICIAL REORGANIZATION

Publicly-Held Company

Corporate Taxpayer ID CNPJ/MF no. 11.395.624/0001-71

Company Registry (NIRE) 35.300.374.797

MATERIAL FACT

BRASIL PHARMA S.A. - IN JUDICIAL REORGANIZATION, a corporation registered in Brazilian Securities Commission ("CVM") as a category A publicly-held corporation, with headquarters in the City of São Paulo, State of São Paulo, at Avenida Presidente Juscelino Kubitschek, No. 1,830, Tower 4, 2nd and 3rd floors, Itaim Bibi, Zip Code 04543-900, with their certificate of incorporation registered at Junta Comercial do Estado de São Paulo under the Company Registry (NIRE) 35.300.374.797, enrolled with the Corporate Taxpayer ID CNPJ/MF under the no. 11.395.624/0001-71 ("Company"), in accordance with the article 157, paragraph 4th, of the Law No. 6,404/1976, as amended ("Corporate Law") and the CVM Instruction No. 358/2002, as amended, hereby informs its shareholders and the market in general that, at the General Debenture Holders' Meeting held on the date hereof, Debenture Holders representing 99.53% (ninety-nine point fifty-three percent) of the totality of the outstanding debentures of the 7th (seventh) Issuance of Debentures, Non-Convertible in Shares, with Secured and Personal Guarantee, in Sole Series, for Private Offering of the Company (respectively, "Debenture Holders" and "Issuance"), have approved to declare the early maturity of the Issuance, without foreclosure of the Issuance's guarantees as of this moment, in view of the filing of the judicial reorganization petition ("pedido de recuperação judicial"), by the Company and other entities of its group, as per disclosed by the Company by means of the Material Fact released on January 9, 2018.

The Company is currently assessing potential impacts of the decision in the context of its corporate and economic reorganization, reiterating its commitment to keep shareholders and the market in general informed concerning the progress of the matters discussed herein and with respect to any other relevant matter to the market.

São Paulo, February 2nd, 2018.

Leonardo Leirinha Souza Campos

Investors Relations Officer